NEXALIS THERAPEUTICS LTD — Director's Dealing 2017

Sep 6, 2017

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001.

Name of entity: Lifespot Health Limited ACN: 611 845 820

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philippa Lewis
Date of appointment	1 September 2017

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

Nil

• See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of	Number & class of Securities
interest
Note: Provide details of the circumstances giving
rise to the relevant interest.
	Nil
Nil

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Non-Executive Director Contract
Nature of interest	Agreement to issue unlisted options
Name of registered holder	To be issued, subject to approval, to Philippa
(if issued securities)	Lewis or her nominee.
No. and class of securities to	Subject to shareholder approval, agreement
which interest relates	to issue 1,000,000 options exercisable at
	$0.20 each expiring 30 September 2021 and
	1,000,000 options exercisable at $0.40 each
	expiring30 June 2022.

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002